BUDAPEST, Hungary—The CEO of Wizz Air is eyeing a stronger presence in Israel, wants to bolster the ULCC’s core Central and Eastern Europe network, and seeks to learn lessons from its Abu Dhabi ...

Ready to unlock your full math potential? 🎓Follow for clear, fun, and easy-to-follow lessons that will boost your skills, build your confidence, and help you master math like a genius—one step at a ...

Abstract: Large neural network models are hard to deploy on lightweight edge devices demanding large network bandwidth. In this article, we propose a novel deep learning (DL) model compression method.

As global efforts to combat climate change intensify, electrochemical CO₂ reduction reaction (CO 2 RR) stands out as a critical technology for converting greenhouse gases into valuable fuels and ...

Qantas is progressively emailing customers impacted by last week’s cyberattack. In a media statement the flagship airline also confirmed that the data of 5.7 million customers was compromised but said ...

1 Mass General Brigham Department of Anesthesiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States 2 Division of Sleep Medicine, Harvard Medical School, Boston, MA, ...

Throughout my career there are a few business books I continue returning to for inspiration and advice. As requests have come in over the years for a short list of recommended reads, it seems helpful ...

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with ...

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing ...

A change in the initiation of donanemab dosing, shifting one vial of donanemab from the first infusion to the third infusion, lowered ARIA-E to 14% compared to 24% in patients receiving the standard ...

Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related imaging abnormalities with edema/effusion at the 24-week primary endpoint ...